Light Chain Bioscience | Novimmune SA
Biotechnology Research
Ch
80 employees
- Employees
- 80
- Contacts
- 2
- Emails
- 2
Light Chain Bioscience | Novimmune SA Overview
- Headquarters
- Ch
- Phone Number
- Available in AeroLeads
- Website
- novimmune.com
- Industry
- Biotechnology Research
- Employees
- 80
- Founded
- 1998
- Funding
- 29.8M
- Company Email
- Available in AeroLeads
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
About Light Chain Bioscience | Novimmune SA
NovImmune has successfully divested EmaCo AG, a newly established company owning emapalumab and related assets to Sobi on 18 July 2019. NovImmune SA will continue to operate and focus on its bispecific technology and associated programs and will rebrand as: “Light Chain Bioscience – A brand of Novimmune SA”. The brand Light Chain Bioscience brings to life the research and development of novel multi-specific antibodies that rely on their light chain for their function. A key distinctive feature of these multispecific antibodies is their native human structure, making them well tolerated and easy to develop. Thus far, NovImmune has advanced seven drug candidates to treat a range of conditions. The Company’s pipeline is a balance of preclinical and clinical candidates for validated and novel targets. NovImmune has established a next-generation antibody drug discovery platform that includes novel bispecific antibody drug capabilities - the simple, stable and smart kappa-lambda-body™. In 2009, NovImmune received the European Biotechnica Award. In 2010, NovImmune entered a partnership with Genentech to advance the Company’s anti-IL17 drug candidate. In addition to pursuing additional drug discovery, development and commercialization partnerships, the Company plans to bring selected drugs to market for focused applications.
Light Chain Bioscience | Novimmune SA Contact Details
- People in AeroLeads
- 3
- With contact data
- 2
- Email contacts
- 2
- 66.7% coverage
Light Chain Bioscience | Novimmune SA Org Chart
Sample employees and titles| Name | Title | Location | Contact |
|---|---|---|---|
| Limin Shang | Director of Pharmacology at Light Chain Bioscience | Geneva, Switzerland |
Email
|
| Oliver Eckelmann, Ph.d. | Entrepreneur, Ceo/coo/cfo Executive & Board Member - Strategy & Leadership for Fast-track Biotech/pharma Start-up & Success |
View
|
|
| Walter Ferlin | Chief Scientific Officer at Light Chain Bioscience | Geneva, Switzerland |
Email
|
Employees by Management Level
Senior / Lead
3 profiles
Individual contributor
3 profiles
Executive
2 profiles
Director
1 profile
Department Contact Coverage
| Department | Contacts | Phone | |
|---|---|---|---|
| General | 3 | 3 | 0 |
Light Chain Bioscience | Novimmune SA Tech Stack
Cloud / infrastructure
1 profile
Compare Similar Companies to Light Chain Bioscience | Novimmune SA
OM Pharma
Pharmaceutical Manufacturing
ADC Therapeutics
Biotechnology Research
AC Immune
Biotechnology Research
Selexis SA
Biotechnology Research
Addex Therapeutics
Biotechnology Research
Amal Therapeutics
Biotechnology Research
Neurosterix
Biotechnology Research
GeNeuro SA
Biotechnology Research
GliaPharm SA
Biotechnology Research
Cellestia Biotech
Biotechnology Research